{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"28.1"},{"groupId":"OG001","value":"53.8"},{"groupId":"OG002","value":"11.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"32"},{"groupId":"OG001","value":"39"},{"groupId":"OG002","value":"18"}],"units":"Participants"}],"description":"The 1999 international response criteria (http://www.ncbi.nlm.nih.gov/pubmed/10655437#) as published by Cheson was used for the definition of target lesions and CT scans were used for response assessment. CR(complete response)/CRu(unconfirmed complete response) requires disappearance of all target lesions; PR (partial response) requires \\>=50% decrease in the sum of the products of the greatest diameters; Overall Response (OR)=CR/CRu+PR.","groups":[{"description":"Patients received Temsirolimus (CCI-779) IV over 30 minutes on days 1,8,15, and 22. Courses repeated every 28 days in the absence of disease progression or unacceptable toxicity. Patients were followed every 8 weeks. Aggressive B-cell lymphoma group was defined as patients with histologic subtypes included diffuse large B-cell lymphoma and transformed follicular lymphoma.","id":"OG000","title":"Aggressive B-cell Lymphoma"},{"description":"Patients received Temsirolimus (CCI-779) IV over 30 minutes on days 1,8,15, and 22. Courses repeated every 28 days in the absence of disease progression or unacceptable toxicity. Patients were followed every 8 weeks. Follicular lymphoma group was defined as patients with histologic subtypes included follicular lymphoma.","id":"OG001","title":"Follicular Lymphoma"},{"description":"Patients received Temsirolimus (CCI-779) IV over 30 minutes on days 1,8,15, and 22. Courses repeated every 28 days in the absence of disease progression or unacceptable toxicity. Patients were followed every 8 weeks. Chronic lymphocytic leukemia group was defined as patients with histologic subtypes included chronic lymphocytic leukemia, small lymphocytic lymphoma, and other indolent lymphomas.","id":"OG002","title":"Chronic Lymphocytic Leukemia"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Up to 6 years","title":"Objective Overall Response Rate","type":"PRIMARY","unitOfMeasure":"percentage of participants"}